➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Harvard Business School
AstraZeneca
Colorcon
Boehringer Ingelheim

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

Heparin sodium - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for heparin sodium and what is the scope of patent protection?

Heparin sodium is the generic ingredient in thirty-eight branded drugs marketed by Hospira, Intl Medication, Luitpold, Parke Davis, Smith And Nephew, Solopak, Abraxis Pharm, Akorn, B Braun Medical Inc, Casi Pharms Inc, Chamberlin Parenterl, Dell Labs, Dr Reddys, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hospira Inc, Lilly, Mylan Labs Ltd, Nanjing King-friend, Organon Usa Inc, Pfizer, Pharm Spec, Pharmacia And Upjohn, Sagent Pharms, Sandoz, Shenzhen Techdow, Watson Labs Inc, West-ward Pharms Int, Baxter Hlthcare, Mcgaw, B Braun, Pharma Serve Ny, and 3M, and is included in eighty-two NDAs. Additional information is available in the individual branded drug profile pages.

There are seventy-seven drug master file entries for heparin sodium. Fourteen suppliers are listed for this compound.

Drug Prices for heparin sodium

See drug prices for heparin sodium

Recent Clinical Trials for heparin sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Xijing HospitalPhase 2/Phase 3
Ain Shams UniversityEarly Phase 1
Indonesia UniversityPhase 1/Phase 2

See all heparin sodium clinical trials

Pharmacology for heparin sodium

US Patents and Regulatory Information for heparin sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 017029-020 Mar 31, 2011 RX Yes Yes   Start Trial   Start Trial   Start Trial
Dell Labs HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 017540-005 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Solopak HEPARIN LOCK FLUSH heparin sodium INJECTABLE;INJECTION 088457-001 Oct 25, 1984 DISCN No No   Start Trial   Start Trial   Start Trial
Mylan Labs Ltd HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 203852-001 Nov 30, 2017 AP RX No No   Start Trial   Start Trial   Start Trial
Chamberlin Parenterl HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 017130-004 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Organon Usa Inc LIQUAEMIN SODIUM heparin sodium INJECTABLE;INJECTION 000552-005 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Mallinckrodt
Dow
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.